Skip to main content

Table 1 Demographics of SLE patients, normal controls and disease controls*

From: Olf1/EBF associated zinc finger protein interfered with antinuclear antibody production in patients with systemic lupus erythematosus

  SLE patients (n = 40) Normal controls (n = 30) Disease controls (n = 18)+
Age, years 33.48 ± 2.11 (14 to 70) 29.23 ± 1.13 (19 to 42) 38.39 ± 2.02 (18 to 54)
Female gender 33 (82.5%) 24 (80.0%) 17 (94.1%)
Disease duration, years 5.91 ± 0.94 (0.08 to 20)   
SLEDAI score 7.70 ± 0.90 (1 to 27)   
Autoantibodies    
   Anti-dsDNA 15 (37.5%)   
   Anti-Sm 19 (47.5%)   
   Anti-SSA 18 (45.0%)   
   Anti-SSB 14 (35.0%)   
   Anti-U1RNP 9 (22.5%)   
  1. * Values are shown by mean ± SEM (range) or number (percentage). There were no significant differences between patients with systemic lupus erythematosus (SLE) and normal controls or disease controls in terms of age and gender.
  2. +Consisted of 18 patients with rheumatoid arthritis. SLEDAI, Systemic Lupus Erythematosus Disease Activity Index.